false 0000868278 0000868278 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 12, 2025

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

626 RXR Plaza, 6th Floor

Uniondale, New York

  11556
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (516) 989-0763

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange of Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events

 

In the Company’s Prospectus Supplement on Form S-3 previously filed on October 15, 2025, the Company previously filed an opinion of counsel pursuant to Item 5.1. The Company has retained new counsel and is submitting a replacement opinion of counsel under Item 9.01. This opinion supersedes, replaces, and renders of no further effect the opinion previously filed under Item 5.1.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

No.   Description
     
5.1.   Opinion of Counsel (includes consent of counsel)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ProPhase Labs, Inc.  
     
By: /s/ Ted Karkus  
  Ted Karkus  
  Chairman of the Board and Chief Executive Officer  
     
Date: Friday, December 19, 2025